Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

Interactions between the dual Bcr/Abl and aurora kinase inhibitor MK-0457 and the histone deacetylase inhibitor vorinostat were examined in Bcr/Abl(+) leukemia cells, including those resistant to imatinib mesylate (IM), particularly those with the T315I mutation. Coadministration of vorinostat drama...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dai, Yun, Chen, Shuang, Venditti, Charis A., Pei, Xin-Yan, Nguyen, Tri K., Dent, Paul, Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2481545/
https://ncbi.nlm.nih.gov/pubmed/18505786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-10-116376
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados